Celerion announced the expansion of specialized high-resolution mass spectrometry (HR-MS) profiling capabilities.
Celerion has created a compelling bioanalytical offering to support drug development at all stages, from in vitro metabolite identification to human ADME profiling studies via SCIEX TripleTOF® 6600+ instrumentation coupled with v.ARC 3 online radio detection and the latest software packages.
“Celerion is pleased to provide this much-needed service to our bioanalytical clients. This metabolite identification capability rounds out our well-known ADME Human Mass Balance offering. We can now continue to work with our clients to define the radiometabolite profile of their drug following human administration to complement earlier in vitro data and further guide drug development,” said Petra Struwe, Ph.D., executive director of the Zurich bioanalytical laboratory.
“These advances enable our clients to rapidly identify and quantify metabolites from human mass balance studies to better understand the potential metabolic breakdown products of novel investigational compounds which may contribute to suboptimal pharmacokinetics and potentially toxic metabolites or even drug-drug interactions,” said Ray Farmen, Ph.D., vice president of global bioanalytical sciences at Celerion. “This expansion is well-aligned with our 10-year anniversary, A Decade of Translating Science Into Medicine, exemplifying the scientific focus driving our success.”